Cargando…

Identification of environmental and genetic factors that influence warfarin time in therapeutic range

Warfarin is an oral anticoagulant prescribed to prevent and treat thromboembolic disorders. It has a narrow therapeutic window and must have its effect controlled. Prothrombin test, expressed in INR value, is used for dose management. Time in therapeutic range (TTR) is an important outcome of qualit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botton, Mariana R., Viola, Patrícia P., Meireles, Mariana R., Bruxel, Estela M., Zuchinali, Priccila, Bandinelli, Eliane, Rohde, Luis E., Leiria, Tiago L. L., Salamoni, Joyce Y. Y., Garbin, Arthur P., Hutz, Mara H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Genética 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198020/ https://www.ncbi.nlm.nih.gov/pubmed/32052826 http://dx.doi.org/10.1590/1678-4685-GMB-2019-0025

Ejemplares similares

Causes and Predictors of In-Hospital Mortality in Patients Admitted with or for Heart Failure at a Tertiary Hospital in Brazil
por: Wajner, André, et al.
Publicado: (2017)

Mediterranean Diet and Other Dietary Patterns in Primary Prevention of Heart Failure and Changes in Cardiac Function Markers: A Systematic Review
por: Sanches Machado d’Almeida, Karina, et al.
Publicado: (2018)

Triceps Skinfold as a Prognostic Predictor in Outpatient Heart Failure
por: Zuchinali, Priccila, et al.
Publicado: (2013)

Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans
por: Steiner, Heidi E., et al.
Publicado: (2021)

Safety and Results of Bioelectrical Impedance Analysis in Patients with Cardiac Implantable Electronic Devices
por: Garlini, Luíza Matos, et al.
Publicado: (2020)

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
por: Çelik, Ahmet, et al.
Publicado: (2016)

A role for neurotransmission and neurodevelopment in attention-deficit/hyperactivity disorder
por: Roman, Tatiana, et al.
Publicado: (2009)

Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin
por: Siddiqui, Safia, et al.
Publicado: (2018)

Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
por: Lee, Siew Ling, et al.
Publicado: (2021)

The Brazilian contribution to Attention-Deficit/Hyperactivity Disorder molecular genetics in children and adolescents
por: Genro, Júlia Pasqualini, et al.
Publicado: (2012)

The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study
por: Kılıç, Salih, et al.
Publicado: (2017)

Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation
por: Marcatto, Leiliane Rodrigues, et al.
Publicado: (2016)

Warfarin overactivity
por: Yamanel, L, et al.
Publicado: (2005)

Evaluation of Bleeding Rate and Time in Therapeutic Range in Patients Using Warfarin Before and During the COVID-19 Pandemic—Warfarin Treatment in COVID-19
por: Emren, Zeynep Yapan, et al.
Publicado: (2021)

Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin
por: Marcatto, Leiliane Rodrigues, et al.
Publicado: (2018)

Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
por: Blum, Daniel, et al.
Publicado: (2019)

Pharmacogenetics of warfarin in a paediatric population: Time in therapeutic range, initial and stable dosing, and adverse effects
por: Hawcutt, Daniel B, et al.
Publicado: (2014)

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
por: Singer, Daniel E., et al.
Publicado: (2015)

Limited English Proficient Patients and Time Spent in Therapeutic Range in a Warfarin Anticoagulation Clinic
por: Rodriguez, Fátima, et al.
Publicado: (2013)

Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation
por: Williams, Brent A., et al.
Publicado: (2017)

Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore
por: Bernaitis, Nijole, et al.
Publicado: (2018)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
por: Singer, Daniel E., et al.
Publicado: (2013)

Is the use of warfarin becoming obsolete?
por: Haykal, Tarek, et al.
Publicado: (2021)

Lower dose direct oral anticoagulation or warfarin in atrial fibrillation. Which one is the best when time on therapeutic range information is available?
por: Luojus, A, et al.
Publicado: (2023)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile
por: Di Maso, Vittorio, et al.
Publicado: (2014)

Influence of Sampling on the Determination of Warfarin and Warfarin Alcohols in Oral Fluid
por: Lomonaco, Tommaso, et al.
Publicado: (2014)

Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation
por: Nelson, Winnie W., et al.
Publicado: (2014)

Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation
por: Defoe, Kimberly, et al.
Publicado: (2021)

Patient adherence to warfarin therapy and its impact on anticoagulation control
por: Mayet, Ahmed Y.
Publicado: (2016)

Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy
por: AL-Eitan, Laith N, et al.
Publicado: (2019)

Multi‐site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos
por: El Rouby, Nihal, et al.
Publicado: (2020)

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
por: Jansson, M., et al.
Publicado: (2023)

Multi‐omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy
por: Bruxel, Estela M., et al.
Publicado: (2021)

Moxifloxacin-warfarin interaction
por: Ji, Yan, et al.
Publicado: (2012)

Warfarin-related Nephropathy
por: Golla, Anvesh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i5glfm1kh9jiss26fq4ef7l7jp